Cargando…

Fluid restriction management in the treatment of COVID-19: a single-center observational study

The relationship between fluid management and the severity of illness, duration of treatment, and outcome of coronavirus disease 2019 (COVID-19) is not fully understood. This study aimed to evaluate whether weight change during hospitalization was associated with COVID-19 severity, length of hospita...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumura, Yosuke, Sugiyama, Takuya, Kondo, Natsuki, Miyahara, Masaya, Hanaoka, Noriyuki, Nagashima, Hideaki, Kasahara, Yuki, Fujiyoshi, Naohiko, Inada, Azusa, Inaba, Shin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569332/
https://www.ncbi.nlm.nih.gov/pubmed/36243779
http://dx.doi.org/10.1038/s41598-022-22389-5
_version_ 1784809832302247936
author Matsumura, Yosuke
Sugiyama, Takuya
Kondo, Natsuki
Miyahara, Masaya
Hanaoka, Noriyuki
Nagashima, Hideaki
Kasahara, Yuki
Fujiyoshi, Naohiko
Inada, Azusa
Inaba, Shin
author_facet Matsumura, Yosuke
Sugiyama, Takuya
Kondo, Natsuki
Miyahara, Masaya
Hanaoka, Noriyuki
Nagashima, Hideaki
Kasahara, Yuki
Fujiyoshi, Naohiko
Inada, Azusa
Inaba, Shin
author_sort Matsumura, Yosuke
collection PubMed
description The relationship between fluid management and the severity of illness, duration of treatment, and outcome of coronavirus disease 2019 (COVID-19) is not fully understood. This study aimed to evaluate whether weight change during hospitalization was associated with COVID-19 severity, length of hospital stay, and route of admission. In this study, we assessed the effectiveness of fluid restriction management in patients with severe COVID-19. COVID-19 patients admitted to our hospital between July 2020 and October 2021 were analyzed. Patients were treated with standard drug therapy based on the Japanese guidelines and respiratory support according to the severity of the disease. Early enteral nutrition, defecation management, and anticoagulation therapy were also administered. Fluid restriction management was performed using furosemide and continuous renal replacement therapy as needed unless hemodynamic instability or hyperlactatemia was present. Patient background, route of admission (ambulance, A; transfer, T), weight at admission and discharge, the severity of illness (oxygen therapy, G1; mechanical ventilation, G2; extracorporeal membrane oxygenation, G3), in-hospital mortality, and length of hospital stay were analyzed. There were 116 subjects: G1 (n = 48), G2 (n = 43), and G3 (n = 25), with ages (median [IQR]) of 58 (47–70), 65 (53–71.5), 56 (51–62) years, 40 (83.3%), 31 (72.1%), and 19 (76.0%) males, respectively. Hospital stays were 4.5 (2–7), 10 (7–16), and 18 (15–26) days, and the in-hospital mortality rates were 0 (0%), 7 (16.3%), and 8 (32%), respectively. Body mass index on admission was 26 (23.1–30.2), 27.1 (22.7–31.1), and 31.5 (27.1–33.1) kg/m(2), and weight loss during admission was 1.1 (0–2.9), 4.6 (2.3–5.7), 9.2 (5.6–10.5) kg (P < 0.001, Jonckheere–Terpstra test. Weight loss in the severe group (G2 + G3) was 3.4 (0.5–5.8) kg [A, n = 12] and 5.6 (4.4–9) kg [T, n = 43] [P = 0.026, Mann–Whitney U test]. The lengths of hospital stay were 5 (2–7), 9 (7–15), and 18 (12–26) days [P < 0.001, Jonckheere–Terpstra test]. In our fluid restriction management, patients with severe COVID-19 had significant longer hospital length of stay, weight loss, especially those who were transferred to the hospital.
format Online
Article
Text
id pubmed-9569332
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-95693322022-10-17 Fluid restriction management in the treatment of COVID-19: a single-center observational study Matsumura, Yosuke Sugiyama, Takuya Kondo, Natsuki Miyahara, Masaya Hanaoka, Noriyuki Nagashima, Hideaki Kasahara, Yuki Fujiyoshi, Naohiko Inada, Azusa Inaba, Shin Sci Rep Article The relationship between fluid management and the severity of illness, duration of treatment, and outcome of coronavirus disease 2019 (COVID-19) is not fully understood. This study aimed to evaluate whether weight change during hospitalization was associated with COVID-19 severity, length of hospital stay, and route of admission. In this study, we assessed the effectiveness of fluid restriction management in patients with severe COVID-19. COVID-19 patients admitted to our hospital between July 2020 and October 2021 were analyzed. Patients were treated with standard drug therapy based on the Japanese guidelines and respiratory support according to the severity of the disease. Early enteral nutrition, defecation management, and anticoagulation therapy were also administered. Fluid restriction management was performed using furosemide and continuous renal replacement therapy as needed unless hemodynamic instability or hyperlactatemia was present. Patient background, route of admission (ambulance, A; transfer, T), weight at admission and discharge, the severity of illness (oxygen therapy, G1; mechanical ventilation, G2; extracorporeal membrane oxygenation, G3), in-hospital mortality, and length of hospital stay were analyzed. There were 116 subjects: G1 (n = 48), G2 (n = 43), and G3 (n = 25), with ages (median [IQR]) of 58 (47–70), 65 (53–71.5), 56 (51–62) years, 40 (83.3%), 31 (72.1%), and 19 (76.0%) males, respectively. Hospital stays were 4.5 (2–7), 10 (7–16), and 18 (15–26) days, and the in-hospital mortality rates were 0 (0%), 7 (16.3%), and 8 (32%), respectively. Body mass index on admission was 26 (23.1–30.2), 27.1 (22.7–31.1), and 31.5 (27.1–33.1) kg/m(2), and weight loss during admission was 1.1 (0–2.9), 4.6 (2.3–5.7), 9.2 (5.6–10.5) kg (P < 0.001, Jonckheere–Terpstra test. Weight loss in the severe group (G2 + G3) was 3.4 (0.5–5.8) kg [A, n = 12] and 5.6 (4.4–9) kg [T, n = 43] [P = 0.026, Mann–Whitney U test]. The lengths of hospital stay were 5 (2–7), 9 (7–15), and 18 (12–26) days [P < 0.001, Jonckheere–Terpstra test]. In our fluid restriction management, patients with severe COVID-19 had significant longer hospital length of stay, weight loss, especially those who were transferred to the hospital. Nature Publishing Group UK 2022-10-15 /pmc/articles/PMC9569332/ /pubmed/36243779 http://dx.doi.org/10.1038/s41598-022-22389-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Matsumura, Yosuke
Sugiyama, Takuya
Kondo, Natsuki
Miyahara, Masaya
Hanaoka, Noriyuki
Nagashima, Hideaki
Kasahara, Yuki
Fujiyoshi, Naohiko
Inada, Azusa
Inaba, Shin
Fluid restriction management in the treatment of COVID-19: a single-center observational study
title Fluid restriction management in the treatment of COVID-19: a single-center observational study
title_full Fluid restriction management in the treatment of COVID-19: a single-center observational study
title_fullStr Fluid restriction management in the treatment of COVID-19: a single-center observational study
title_full_unstemmed Fluid restriction management in the treatment of COVID-19: a single-center observational study
title_short Fluid restriction management in the treatment of COVID-19: a single-center observational study
title_sort fluid restriction management in the treatment of covid-19: a single-center observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569332/
https://www.ncbi.nlm.nih.gov/pubmed/36243779
http://dx.doi.org/10.1038/s41598-022-22389-5
work_keys_str_mv AT matsumurayosuke fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy
AT sugiyamatakuya fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy
AT kondonatsuki fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy
AT miyaharamasaya fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy
AT hanaokanoriyuki fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy
AT nagashimahideaki fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy
AT kasaharayuki fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy
AT fujiyoshinaohiko fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy
AT inadaazusa fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy
AT inabashin fluidrestrictionmanagementinthetreatmentofcovid19asinglecenterobservationalstudy